tumor activity, including durable responses, in patients with mBCC after progression or intolerance on HHI therapy.

Acknowledgements Editorial acknowledgment: Medical writing support was provided by Cindi Hoover, PhD of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc. and Sanofi.

Ethics Approval The study protocols and all amendments were approved by the institutional review board at each participating study site. The study was conducted in accordance with the principles of the Declaration of Helsinki and with Good Clinical Practice guidelines as defined by the International Conference on Harmonization. All patients provided written informed consent before enrollment.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0428

LONG-TERM ANALYSIS OF MASTERKEY-265 PHASE 1B TRIAL OF TALIMOGENE LAHERPAREPVEC (T-VEC) PLUS PENUMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE STAGE IIIIB-IVM1C MELANOMA

1Georgina Long*, 2Reinhard Dummer, 3Douglas Johnson, 4Olivier Michielin, 5Salvador Martin-Algarra, 6Sheryl Treichel, 7Edward Chan, 8Scott Diede, 9Antoni Ribas.
1Melanoma Institute Australia, The University of Sydney and Royal North Shore and Mater Hospitals, Sydney, Australia; 2University of Zurich, Zurich, SC, Switzerland; 3Vanderbilt University Medical Center, Nashville, TN, USA; 4Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 5Clinica Universidad de Navarra (CUN), Medical School of the University of Navarra, Pamplona, Spain; 6Amgen Inc., Thousand Oaks, CA, USA; 7Merck and Co., Inc., Kenilworth, NJ, USA; 8University of California at Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA

Background Previous findings from the MASTERKEY-265 phase 1b study showed that the combination of T-VEC and pembrolizumab was well tolerated and produced a high complete response (CR) rate of 43% in patients with advanced melanoma.1 The 3-year progression-free survival (PFS) and overall survival (OS) rates at that time were 53.6% and 71%, respectively. Here, we report the results of the long-term follow-up efficacy analyses.

Methods The MASTERKEY-265 phase 1b trial (NCT02263508) was an open-label, single-arm study that enrolled patients who had unresectable, stage IIIIB-IVM1c melanoma with injectable, measurable lesions and no prior systemic treatment. T-VEC was administered intradermally at the tumor site. The study site. The study was conducted in accordance with the principles of the Declaration of Helsinki and with Good Clinical Practice guidelines as defined by the International Conference on Harmonization. All patients provided written informed consent before enrollment.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0429

A PHASE II STUDY OF NIVOLUMAB + BMS-986016 (RELATLIMAB) IN PATIENTS WITH METASTATIC UVEAL MELANOMA (UM) (CA224–094)

1Jose Lutzky*, 2Jose Lutzky, 3Lynn Feun, 4William Harbour. 1Jose Lutzky, 2Jose Lutzky, 3Lynn Feun, 4William Harbour. 1University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA; 2U of Miami Bascom Palmer Eye Institute, Miami, FL, USA

Background Fifty percent of patients with uveal melanoma (UM) develop metastatic disease, surviving 6–12 months from metastatic diagnosis. Liver-directed therapies, immunotherapy, targeted therapy and chemotheraphy have limited activity. Lymphocyte activation gene 3 (LAG-3) is an immune checkpoint receptor associated with decreased T-cell effector function and tumor escape. Preclinical models have shown that dual inhibition of LAG-3 and PD-1 blockade generates synergestic anti-tumor activity.1 In uveal melanoma, CD8+ T cells express the checkpoint receptor LAG3 to a greater extent than PD1 or CTLA4.2–3 This recent discovery nominates LAG3 as a potential candidate for checkpoint inhibitor immunotherapy in UM.

Methods This is an open-label, single arm, single site investigator-initiated phase II study. Based on Simon two-stage min-max design, 13 patients will be enrolled in Stage 1. If at least one response is noted, the study will proceed to Stage 2 and enroll additional 14 patients. The null hypothesis will be rejected if 4 or more responses are observed among 27 patients. This design achieves 5% type I error and 80% power when the true ORR is 20%.Main eligibility criteria includes patients with biopsy proven metastatic uveal melanoma, previously untreated with PD-1, CTLA-4 and/or LAG-3 blocking antibodies and in good performance status.Enrolled patients will be treated in the outpatient setting. Nivolumab 480 mg will be mixed in the same bag with relatlimab 160 mg and administered intravenously over 60 minutes every 4 weeks until disease progression or intolerable toxicity for up to 24 months.The primary endpoint is best objective response rate (ORR). Secondary endpoints include disease control rate (DCR), progression-free survival (PFS), overall survival (OS), median duration of response (mDOR), and adverse events.
Correlative studies will evaluate pre- and post-treatment characteristics of T cells in the tumor microenvironment and blood.

**Results**

N/A

**Conclusions**

N/A

**Ethics Approval**

The study was approved by the University of Miami Sylvester Cancer Center PRMC #20200847

**Consent**

N/A

**REFERENCES**


http://dx.doi.org/10.1136/jitc-2020-SITC2020.0430

**431** PROSPECTIVE, RANDOMIZED TRIAL OF THE TUMOR LYSATE, PARTICLE ONLY VACCINE COMPARED TO THE TUMOR LYSATE, PARTICLE-LOADED, DENDRITIC CELL VACCINE TO PREVENT RECURRENCE FOR RESECTED STAGE III/IV MELANOMA

1Patrick McCarthy*, 1Lexy Adams, 1Robert Chick, 1Guy Clifton, 1Timothy Vreeland, 1Anne O'Shea, 1Phillip Kemp Bohan, 1Annelies Hickeron, 1Jessica Camp, 1John Myers, 1Tommy Brown, 1Diane Hale, 2Mark Fairley, 3John Hyngstrom, 4Adam Berger, 5James Jakub, 6Jeffrey Susman, 7Montaseh Shaheen, 8Thomas Wagner, 9George Peoples.

1Brooke Army Medical Center, San Antonio, TX, USA; 2The Los Angeles Angeles Clinic, CA, USA; 3University of Utah, Salt Lake City, UT, USA; 4Thomas Jefferson University, Philadelphia, PA, USA; 5Mayo Clinic, Rochester, MN, USA; 6University of Cincinnati, Cincinnati, OH, USA; 7University of Arizona, Phoenix, AZ, USA; 8Orbis Health Solutions, Greenville, SC, USA; 9Cancer Vaccine Development Group, San Antonio, TX, USA

**Background**

The autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is safe and effective in improving 24 and 36-month disease-free survival (DFS) in patients (pts) with resected stage III/IV melanoma who completed the primary vaccine series. The tumor lysate, particle only (TLPO) vaccine has been developed to accelerate production by omitting DC isolation and ex vivo loading in favor of in vivo phagocytosis of the TL-loaded particles. We are currently conducting a randomized and double-blind trial of the TLPO vs TLPLDC to improve DFS and overall survival (OS) in patients with resected stage melanoma.

**Methods**

Patients with stage III/IV melanoma who were clinically disease-free after standard of care therapies were randomized to receive TLPO vs TLPLDC (2:1) as a continuation of the phase IIb trial comparing TLPLDC vs placebo (2:1). For the TLPLDC vaccine, autologous TL was loaded into yeast cell wall particles (YCWP) which were then phagocytized by isolated autologous DC ex vivo. For the placebo DC were loaded with empty YCWP. For TLPO, the autologous TL-loaded YCWP were coated with a chemoattractant and injected intradermally for in vivo phagocytosis. Some patients in the TLPLDC arm received G-CSF prior to DC harvest to minimize blood draw (60 mL instead of 120 mL without G-CSF). For all arms, six vaccine/placebo doses were administered intradermally at 0, 1, 2, 6, 12, and 18 mos. Data was analyzed by an intention-to-treat (ITT) analysis for DFS and OS by the Kaplan-Meier method and compared by log-rank test.